Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel - PubMed (original) (raw)
Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel
Peter Jochen Olbert et al. Anticancer Drugs. 2006 Sep.
Abstract
Docetaxel has shown promise for the treatment of hormone-refractory prostate cancer and has become the standard of care. The flare phenomenon is a known entity in androgen-deprivation therapy of advanced prostate cancer and it has also been described in palliative chemotherapy of hormone-refractory prostate cancer. The aim of this study was to evaluate the clinical impact of a prostate-specific antigen flare phenomenon in docetaxel-treated hormone-refractory prostate cancer patients. From December 2002 to August 2005, we treated 44 patients with hormone-refractory prostate cancer applying docetaxel-based regimens. Prostate-specific antigen levels were determined before therapy and weekly thereafter. Patients were divided into three groups: response (group 1), progression (group 2) and flare (group 3). Flare was defined as initially rising prostate-specific antigen under therapy, dropping thereafter to values below baseline. The groups were compared for overall survival by Kaplan-Meier analysis. We observed a prostate-specific antigen flare phenomenon in eight (18%) of 44 evaluable patients; 24 (54.5%) patients were primary responders and 12 (27.3%) experienced progressive disease. In group 3, prostate-specific antigen levels rose to 107-180% from baseline and then dropped to 21-68%. Kaplan-Meier analysis showed significantly better overall median survival for groups 1 (18 months, P=0.0005) and 3 (19 months, P=0.006) than for group 2 (7 months). Survival in groups 1 and 3 was comparable. Grade 3 and 4 toxicity was below 5% and equally distributed between the 3 groups. In our limited patient cohort, prostate-specific antigen flare phenomenon does not seem to be a clinically relevant issue in terms of overall survival. Thus, an initial rise of prostate-specific antigen under docetaxel therapy in hormone-refractory prostate cancer does not indicate therapeutic failure and should not lead to early withdrawal from therapy in the absence of clinical signs of progression.
Similar articles
- Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K. Kijima T, et al. BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28. BJU Int. 2012. PMID: 22369348 - Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer.
Sella A, Sternberg CN, Skoneczna I, Kovel S. Sella A, et al. BJU Int. 2008 Dec;102(11):1607-9. doi: 10.1111/j.1464-410X.2008.07873.x. Epub 2008 Oct 2. BJU Int. 2008. PMID: 18990177 - Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
Picus J, Schultz M. Picus J, et al. Semin Oncol. 1999 Oct;26(5 Suppl 17):14-8. Semin Oncol. 1999. PMID: 10604263 Clinical Trial. - PSA surge/flare-up in patients with castration-refractory prostate cancer during the initial phase of chemotherapy.
Nelius T, Filleur S. Nelius T, et al. Prostate. 2009 Dec 1;69(16):1802-7. doi: 10.1002/pros.21024. Prostate. 2009. PMID: 19676083 Review. - Therapeutic options in androgen-independent prostate cancer: building on docetaxel.
Petrylak D. Petrylak D. BJU Int. 2005 Dec;96 Suppl 2:41-6. doi: 10.1111/j.1464-410X.2005.05946.x. BJU Int. 2005. PMID: 16359438 Review.
Cited by
- Identification of blood lipid markers of docetaxel treatment in prostate cancer patients.
Finnerty MC, Leach FE 3rd, Zakharia Y, Nepple KG, Bartlett MG, Henry MD, Cummings BS. Finnerty MC, et al. Sci Rep. 2024 Sep 27;14(1):22069. doi: 10.1038/s41598-024-73074-8. Sci Rep. 2024. PMID: 39333185 Free PMC article. - 'FLARE' of tumor marker in advanced gastric cancer treated with first-line systemic therapy.
Zhang F, Zhai M, Yang J, Zhao L, Lin Z, Wang J, Zhang T, Yu D. Zhang F, et al. Therap Adv Gastroenterol. 2022 Sep 28;15:17562848221124029. doi: 10.1177/17562848221124029. eCollection 2022. Therap Adv Gastroenterol. 2022. PMID: 36187367 Free PMC article. - mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease.
Hartrampf PE, Bundschuh RA, Weinzierl FX, Serfling SE, Kosmala A, Seitz AK, Kübler H, Buck AK, Essler M, Werner RA. Hartrampf PE, et al. Eur J Nucl Med Mol Imaging. 2022 Nov;49(13):4727-4735. doi: 10.1007/s00259-022-05910-w. Epub 2022 Jul 19. Eur J Nucl Med Mol Imaging. 2022. PMID: 35852555 Free PMC article. - Prostate-specific antigen flare induced by 223RaCl2 in patients with metastatic castration-resistant prostate cancer.
Castello A, Macapinlac HA, Lopci E, Santos EB. Castello A, et al. Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2256-2263. doi: 10.1007/s00259-018-4051-y. Epub 2018 May 21. Eur J Nucl Med Mol Imaging. 2018. PMID: 29785515 - Association of early PSA decline and time to PSA progression in abiraterone acetate-treated metastatic castration-resistant prostate cancer; a post-hoc analysis of Japanese phase 2 trials.
Nakayama M, Kobayashi H, Takahara T, Oyama R, Imanaka K, Yoshizawa K. Nakayama M, et al. BMC Urol. 2016 Jun 8;16(1):27. doi: 10.1186/s12894-016-0148-4. BMC Urol. 2016. PMID: 27278777 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical